2,486 reports of this reaction
2.9% of all WARFARIN SODIUM reports
#3 most reported adverse reaction
DYSPNOEA is the #3 most commonly reported adverse reaction for WARFARIN SODIUM, manufactured by Upsher-Smith Laboratories, LLC. There are 2,486 FDA adverse event reports linking WARFARIN SODIUM to DYSPNOEA. This represents approximately 2.9% of all 87,043 adverse event reports for this drug.
WARFARIN SODIUM has an overall safety score of 92 out of 100. Patients taking WARFARIN SODIUM who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for WARFARIN SODIUM, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for WARFARIN SODIUM:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 2,486 FDA reports for WARFARIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.9% of all adverse event reports for WARFARIN SODIUM, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking WARFARIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.